Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022

Organoid modeling of the tumor immune microenvironment

Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis

Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863

Management of toxicities of immune checkpoint inhibitors

Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817

The Next Decade of Immune Checkpoint Therapy

Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750

PD-L1 expression in human cancers and its association with clinical outcomes

Yu, J., Wang, X., Teng, F., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105862 · Cited by 787

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry

Bassani-Sternberg, M., Bräunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13404 · Cited by 693

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)

Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589

Immune checkpoint inhibitors and cardiovascular toxicity

Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30457-1 · Cited by 575

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., & Carpentier, A. F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.001 · Cited by 571

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Capone, M., Giannarelli, D., Mallardo, D., Madonna, G., Festino, L., Grimaldi, A. M., Vanella, V., Simeone, E., Paone, M., Palmieri, G., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0383-1 · Cited by 497

Drug development in the era of precision medicine

Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., Voloschin, A., Ramkissoon, S. H., Ligon, K. L., Latek, R., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox208 · Cited by 486

Targeting the gut and tumor microbiota in cancer

Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496

Cancer immunotherapies: advances and bottlenecks

Rui, R., Zhou, L., & He, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212476 · Cited by 484

PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy

Salmaninejad, A., Valilou, S. F., Shabgah, A. G., Aslani, S., Alimardani, M., Pasdar, A., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28358 · Cited by 445

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

Belum, V. R., Benhuri, B., Postow, M. A., Hellmann, M. D., Lesokhin, A. M., Segal, N. H., Motzer, R. J., Wu, S., Busam, K. J., Wolchok, J. D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.010 · Cited by 418

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406

Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors

Nomura, M., Nagatomo, R., Doi, K., Shimizu, J., Baba, K., Saito, T., Matsumoto, S., Inoue, K., & Muto, M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.2895 · Cited by 396

The role of gut microbiota in cancer treatment: friend or foe?

Cheng, W. Y., Wu, C.-Y., & Yu, J. (2020) · Gut · doi:10.1136/gutjnl-2020-321153 · Cited by 384

A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors

de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap

Song, W., Shen, L., Wang, Y., Liu, Q., Goodwin, T. J., Li, J., Dorosheva, O., Liu, T., Liu, R., & Huang, L. (2018) · Nature Communications · doi:10.1038/s41467-018-04605-x · Cited by 375

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Kugel, C. H., Douglass, S. M., Webster, M. R., Kaur, A., Liu, Q., Yin, X., Weiss, S. A., Darvishian, F., Al-Rohil, R. N., Ndoye, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1116 · Cited by 367

Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications

Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

Ascierto, P. A., Long, G. V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4514 · Cited by 352

Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape

Garg, A. D., Coulie, P. G., Van den Eynde, B. J., & Agostinis, P. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.006 · Cited by 340

Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy

Constantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.008 · Cited by 342

Immune checkpoint inhibitors in challenging populations

Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339

CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects

Dalvin, L. A., Shields, C. L., Orloff, M., Sato, T., & Shields, J. A. (2018) · Retina · doi:10.1097/iae.0000000000002181 · Cited by 336

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx026 · Cited by 333

Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights

Faje, A. (2016) · Pituitary · doi:10.1007/s11102-015-0671-4 · Cited by 326

The immune system and cancer evasion strategies: therapeutic concepts

Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

Diem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M., & Larkin, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.467 · Cited by 308

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285

Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms

Delivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278

Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy

Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250

Markers of T Cell Senescence in Humans

Xu, W., & Larbi, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081742 · Cited by 261

Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients

Rogado, J., Sánchez-Torres, J. M., Romero-Laorden, N., Ballesteros, A. I., Pacheco-Barcia, V., Ramos-Leví, A., Arranz, R., Lorenzo, A., Gullón, P., Donnay, O., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.014 · Cited by 255

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0193 · Cited by 248

The Extrinsic and Intrinsic Roles of PD‐L1 and Its Receptor PD‐1: Implications for Immunotherapy Treatment

Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243

TIM-3, a promising target for cancer immunotherapy

He, Y., Cao, J., Zhao, C., Li, X., Zhou, C., & Hirsch, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170385 · Cited by 235

Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials

Larkin, J., Lao, C. D., Urba, W. J., McDermott, D. F., Horak, C., Jiang, J., & Wolchok, J. D. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1184 · Cited by 223

Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy

Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W. L., & Smyth, M. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0933 · Cited by 223

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis

Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0336-8 · Cited by 218

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

Indini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F., & Del Vecchio, M. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2819-x · Cited by 202

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study

Koelzer, V. H., Rothschild, S. I., Zihler, D., Wicki, A., Willi, B., Willi, N., Voegeli, M., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0117-1 · Cited by 200

Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies

Chen, J. H., Pezhouh, M. K., Lauwers, G. Y., & Masia, R. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000829 · Cited by 186

Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer

Phillips, T., Simmons, P., Inzunza, H. D., Cogswell, J., Novotny, J., Taylor, C., & Zhang, X. (2015) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000256 · Cited by 189

Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1

Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185

Gut microbiome modulates efficacy of immune checkpoint inhibitors

Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179

Endocrine side effects of cancer immunotherapy

Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177

Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study

Yamauchi, I., Sakane, Y., Fukuda, Y., Fujii, T., Taura, D., Hirata, M., Hirota, K., Ueda, Y., Kanai, Y., Yamashita, Y., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0562 · Cited by 169

Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis

Park, H. J., Kim, K. W., Pyo, J., Suh, C. H., Yoon, S., Hatabu, H., & Nishino, M. (2020) · Radiology · doi:10.1148/radiol.2020200443 · Cited by 162

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H., Yamazaki, N., Kitano, S., Yamamoto, N., & Ohe, Y. (2018) · Cancer Science · doi:10.1111/cas.13800 · Cited by 158

Non-conventional Inhibitory CD4+Foxp3−PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity

Zappasodi, R., Budhu, S., Hellmann, M. D., Postow, M. A., Senbabaoglu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., Li, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.009 · Cited by 142

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy

Yao, H., Wang, H., Li, C., Fang, J.-Y., & Xu, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01774 · Cited by 141

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

Costa, R., Carneiro, B. A., Agulnik, M., Rademaker, A. W., Pai, S. G., Villaflor, V. M., Cristofanilli, M., Sosman, J. A., & Giles, F. J. (2017) · Oncotarget · doi:10.18632/oncotarget.13315 · Cited by 123

Immune checkpoint inhibitors in cancer therapy

Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119

Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy

Tay, R. Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S., & Haydon, A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.253 · Cited by 119

PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations

Scheel, A. H., Ansén, S., Schultheis, A. M., Scheffler, M., Fischer, R. N., Michels, S., Hellmich, M., George, J., Zander, T., Brockmann, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1131379 · Cited by 111

Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma

Khoja, L., Maurice, C., Chappell, M., MacMillan, L., Al-Habeeb, A. S., Al-Faraidy, N., Butler, M. O., Rogalla, P., Mason, W., Joshua, A. M., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0186 · Cited by 109

Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management

Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100

Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management

Huffman, B. M., Kottschade, L. A., Kamath, P. S., & Markovic, S. N. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000374 · Cited by 100

Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin

Jain, V., Mohebtash, M., Rodrigo, M. E., Ruiz, G., Atkins, M. B., & Barac, A. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000239 · Cited by 96

Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study

Okada, N., Kawazoe, H., Takechi, K., Matsudate, Y., Utsunomiya, R., Zamami, Y., Goda, M., Imanishi, M., Chuma, M., Hidaka, N., et al. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.004 · Cited by 96

Aging, immune senescence, and immunotherapy: a comprehensive review

Elias, R., Hartshorn, K., Rahma, O., Lin, N., & Snyder-Cappione, J. E. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.08.006 · Cited by 96

Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them

Habashy, K. J., Mansour, R., Moussalem, C., Sawaya, R., & Massaad, M. J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01864-w · Cited by 95

The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer

Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92

PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review

Caccese, M., Indraccolo, S., Zagonel, V., & Lombardi, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.12.002 · Cited by 87

Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities

Cousin, S., & Italiano, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2569 · Cited by 83

The evolutionary legacy of immune checkpoint inhibitors

Kaushik, I., Ramachandran, S., Zabel, C., Gaikwad, S., & Srivastava, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.020 · Cited by 79

Trial watch: immune checkpoint blockers for cancer therapy

Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73

Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors

Lim, E. L., Cugliandolo, F. M., Rosner, D. R., Gyori, D., Roychoudhuri, R., & Okkenhaug, K. (2018) · JCI Insight · doi:10.1172/jci.insight.120626 · Cited by 66